Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19

 Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19

Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19

Shots:

  • The company reported the results of an expanded access trial for Zofin in patients with COVID-19 which was conducted in Houston, TX
  • The trial met EPs for safety & efficacy i.e., improved pulmonary opacities in chest X-rays which showed 83% of patients had normal lung imaging, indicated complete recovery @30 days treatment, improved biomarker levels vs respective control with p-values, mitigated mild and moderate symptoms, was well tolerated with no AEs
  • The company will submit this data to FDA for a requested amendment to their approved IND to perform a PBO-controlled P-II clinical trial and also plans to submit results for scientific peer review & publication

Click here to­ read full press release/ article | Ref: Business Wire | Image: BioInformant

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post